Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › risankizumab

risankizumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of risankizumab

25 trials tracked of risankizumab: 15 in phase 3 or 4 and 11 with published results. The most-cited published study has 302 citations.

25Trials tracked
15Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 2 Phase 3 13 Phase 2 10
  1. Phase 3 BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 302 cited
  2. Phase 3 BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment Completed · 217 cited
  3. Phase 3 BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 57 cited
  4. Phase 3 BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 56 cited
  5. Phase 3 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) Completed · 51 cited
  6. Phase 3 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis Completed · 27 cited
Show 19 more trials
  1. Phase 3 A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Completed · 22 cited
  2. Phase 4 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy Completed · 21 cited
  3. Phase 3 A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis Completed · 18 cited
  4. Phase 4 Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis Completed · 6 cited
  5. Phase 3 A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab Completed · 4 cited
  6. Phase 3 A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy Completed
  7. Phase 3 A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis Completed
  8. Phase 3 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement Completed
  9. Phase 3 A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms Completed
  10. Phase 2 High Dose Risankizumab for Psoriasis Completed
  11. Phase 2 Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma Completed
  12. Phase 2 A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis Completed
  13. Phase 2 ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19 Completed
  14. Phase 2 A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171) Completed
  15. Phase 2 A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Completed
  16. Phase 2 BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS) Completed
  17. Phase 2 Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed
  18. Phase 2 BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis Completed
  19. Phase 2 BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis Completed

Showing the 25 most-cited and recently-updated of 25 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Upadacitinib and IL-23 inhibitors show favorable efficacy and tolerability in moderate-to-severe ulcerative colitis
Drug Pipeline Meta-analysis
Upadacitinib and IL-23 inhibitors show favorable efficacy and tolerability in moderate-to-severe ulcerative colitis New Data Compares Treatments for Moderate to Severe Ulcerative Colitis
This network meta-analysis evaluates Upadacitinib, Ustekinumab, Risankizumab, Guselkumab, and Mirikizumab for moderate-to-severe ulcerative …
New research compares several medications for ulcerative colitis, highlighting different options for achieving remission and managing side e…
Frontiers Oct 16, 2026
Extended Risankizumab Benefits Initial Nonresponders in Ulcerative Colitis
Drug Pipeline RCT
Extended Risankizumab Benefits Initial Nonresponders in Ulcerative Colitis Over half of ulcerative colitis patients found relief with longer treatment
Over 50% of patients with ulcerative colitis who did not respond to initial risankizumab achieved clinical response with 12 more weeks of ex…
More than half of patients with ulcerative colitis who did not respond to initial treatment found clinical response with extended risankizum…
May 1, 2026